Use of high efficacy, lower dose triple therapy to reduce side effects of eradicating Helicobacter pylori

Objectives: To evaluate two triple-therapy (TT) regimens of colloidal bismuth subcitrate (CBS), metronidazole, and tetracycline HCl in eradicating Helicobacter pylori, with particular attention to the frequency of resulting adverse effects of the two therapies. Methods: A prospective, randomized controlled trial was conducted in patients with symptoms of dyspepsia who were positive for H. pylori. Subjects received a 14-day course of either 4×/day therapy of CBS (108 mg), tetracycline HCl (500 mg), and metronidazole (250 mg), or 5×/day therapy of CBS (108 mg), tetracycline HCl (250 mg), and metronidazole (200 mg). H. pylori status was determined endoscopically by urease test, histology, and culture